Semax and Selank are distinct synthetic neuropeptides with different parent sequences, research histories, and experimental questions. The original overview of this page asks readers to keep ACTH-derived and tuftsin-derived designs distinct, to separate neuroscience endpoints, and to document identity for each short synthetic peptide.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not a ranking, not claims about a Velnacor lot, and not instructions for use in people or animals.
ACTH-derived versus tuftsin-derived design
Dolotov and colleagues identified Semax as the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, an analogue of ACTH(4-10), and reported effects on BDNF/trkB measures and conditioned avoidance in rat hippocampus (Dolotov et al., 2006). Eremin and colleagues used the same sequence description in a rodent neurochemistry study (Eremin et al., 2005). A Semax identity note is at What Is Semax?.
Kasian and colleagues described Selank as including the tuftsin fragment Thr-Lys-Pro-Arg, elongated at the C terminus with Pro-Gly-Pro, and their methods name the Nα-Thr-Lys-Pro-Arg-Pro-Gly-Pro diacetate salt (Kasian et al., 2017). Vyunova and colleagues discussed Selank as a heptapeptide in a review of molecular aspects of its reported activity (Vyunova et al., 2018). A Selank identity note is at What Is Selank?.
Those parent sequences are not interchangeable. Shared shipping or a combination SKU does not merge an ACTH-derived analogue with a tuftsin-derived analogue.
Why this is not a ranking
Dolotov and Eremin reported rodent hippocampal and monoamine/behavioral observations for Semax. Kasian and colleagues reported rat elevated-plus-maze findings for Selank, alone and with diazepam, with and without unpredictable chronic mild stress (Kasian et al., 2017). Those papers use different designs and endpoints. They are not a head-to-head table, and they are not use instructions.
Citation flag. A single peer-reviewed study that compared Semax and Selank head-to-head in one experimental design was not verified for this draft. The comparison is a documentation framework built from identity papers and from findings reported for each analogue in its own literature.
Identity testing and separate lot files
Each short peptide needs its own sequence, purity, content, and lot records. How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, and lot traceability apply independently to each line item.
Catalog records exist for Semax, Selank, and a combination SKU. There is not a standalone public landing page for every name; use the product directory and the COA Library, then confirm each SKU in the inquiry. Combination presentations need their own identifiers. For packing at supply scale, see wholesale peptides.
Assay selection is part of the comparison problem. A hippocampal BDNF or avoidance design used with Semax is not the same endpoint as an elevated-plus-maze design used with Selank. Vehicle, timing, and the exact salt form named in a methods section belong in the receiving file for each analogue, but they are not copied here as a laboratory procedure. A review article that discusses Selank in heptapeptide terms is useful for identity; it is not a new controlled comparison.
Selected published literature
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108. PubMed 16996037.
- Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005;30(12):1493-1500. doi:10.1007/s11064-005-8826-8. PubMed 16362768.
- Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology. 2017;2017:5091027. doi:10.1155/2017/5091027. PubMed 28280289.
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein & Peptide Letters. 2018;25(10):914-923. doi:10.2174/0929866525666180925144642. PubMed 30255741. Review article; cited for heptapeptide identity, not as a use instruction.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.